Last reviewed · How we verify
NCT05437094
Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740
Phase 1 trial testing CRD-740 in Clinical Pharmacology in 20 participants. Completed in 10 August 2022.
3 August 2022
Quick facts
| Lead sponsor | Cardurion Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 27 June 2022 |
| Primary completion | 3 August 2022 |
| Estimated completion | 10 August 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- CRD-740 — full drug profile →
- Itraconazole — full drug profile →
Conditions studied
- Clinical Pharmacology — all drugs for Clinical Pharmacology →
- Pharmacokinetics — all drugs for Pharmacokinetics →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
- Heart Failure — all drugs for Heart Failure →
Sponsor
Cardurion Pharmaceuticals, Inc. — full company profile →
Who can join
Adults 18 to 55, any sex, with Clinical Pharmacology or Pharmacokinetics. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 1, single-site, open-label, fixed sequence crossover study to investigate the effect of coadministration of itraconazole on the pharmacokinetics of CRD-740 in healthy male and female subjects. Subjects will be admitted into the study site on Day -1 and will be confined to the study site until discharge on Day 16. Subjects will receive CRD-740 orally on Days 1 and 10. Itraconazole will be given once daily, orally, on Days 7 through 15.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05437094
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of CRD-740
Trials testing the same drug.
- NCT05409183 — Effectiveness of CRD-740 in Heart Failure · Phase 2 · terminated
Other recruiting trials for Clinical Pharmacology
Currently open trials in the same condition.
- NCT07374224 — A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet · Phase 1 · recruiting
Other Cardurion Pharmaceuticals, Inc. trials
Trials by the same sponsor.
- NCT06215586 — Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF) · Phase 2 · completed
- NCT06215911 — A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle- · Phase 2 · completed
- NCT06005428 — Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) · Phase 2 · terminated
- NCT05409183 — Effectiveness of CRD-740 in Heart Failure · Phase 2 · terminated
- NCT04411082 — A Study of IMR-687 in Subjects With Beta Thalassemia · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05437094 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cardurion Pharmaceuticals, Inc.
- Last refreshed: 15 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05437094.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing